GlassScriptPhysician profile
Greesh John
NPI 1922316272
$16,313.50
in general payments reported to CMS, 2019-2025
31 companies · $5,692 in 2025
The $5,692 reported for 2025 was more than what 94% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,778 · 2020: $2,330 · 2021: $2,091 · 2022: $682 · 2023: $1,181 · 2024: $559 · 2025: $5,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $4,768 · Food and Beverage: $2,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $4,768.00 |
| Food and Beverage | $2,664.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,014.77 | 2019-2025 | Proclaim, Ep-Workmate, Eterna |
| International Rehabilitative Sciences, INC | $4,796.62 | 2025 | Rs-4i Plus With Intersperse, Rs-Lbg, Rs-Fbg. Rs-Sg |
| Medtronic USA, INC. | $1,556.01 | 2019-2020 | |
| Boston Scientific Corporation | $850.33 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Si-Bone, INC. | $818.21 | 2019-2023 | |
| Vertos Medical, INC. | $717.27 | 2021-2024 | Mild Device Kit |
| Nevro Corp. | $653.41 | 2019-2024 | Senza |
| Medtronic, INC. | $391.97 | 2021-2025 | Synchromedii |
| Collegium Pharmaceutical, INC. | $275.13 | 2020-2025 | Belbuca |
| Globus Medical, INC. | $218.82 | 2025 | Senza |
| Grt US Holding, INC. | $150.03 | 2021-2022 | |
| Biotronik Nro, INC. | $143.65 | 2023 | Biotronik |
| Averitas Pharma INC. | $126.48 | 2023-2025 | Qutenza |
| Scilex Pharmaceuticals INC. | $84.75 | 2021-2023 | Ztlido |
| Nalu Medical, INC. | $71.26 | 2021-2025 | Nalu Neurostimulation System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $52.07 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.18 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $41.99 | 2024-2025 | |
| Horizon Therapeutics Plc | $41.31 | 2019-2021 | |
| Amgen INC. | $37.08 | 2025 | Krystexxa |
| Abbvie INC. | $36.42 | 2022-2025 | |
| Electronic Waveform Lab, INC. | $30.56 | 2024 | |
| Fidia Pharma USA INC. | $27.77 | 2023 | Hymovis, Triluron |
| Redhill Biopharma INC. | $27.02 | 2021 | |
| Allergan, INC. | $17.96 | 2020 | |
| Curonix LLC | $16.16 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Valinor Pharma, LLC | $15.78 | 2025 | Movantik |
| Idorsia Pharmaceuticals US INC | $15.50 | 2024 | Quviviq |
| Saluda Medical Americas, INC. | $14.60 | 2024 | Evoke |
| Orexo US, INC. | $13.51 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.88 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greesh John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.